The Microfluidics Consortium Meeting 2025 is poised to become a milestone event in the microtechnology landscape, uniting pioneering researchers, biotech startups, and industry veterans in Lausanne, Switzerland, on April 8–9. Hosted at the AGORA Cancer Research Centre, this forum will focus on transformative breakthroughs in glass microfluidic devices (—a key enabler of next-generation biotech and medtech solutions.
Why Glass? The Strategic Advantages for Microfluidics (MF)
Glass is rapidly overtaking traditional materials like polydimethylsiloxane (PDMS), polycarbonate, or silicon in lab-on-chip (LOC), point-of-care diagnostics (POC), organ-on-chip (OOC), and next-generation sequencing (NGS) applications. Its superiority lies in a combination of:
At FEMTOprint SA, we leverage our proprietary FEMTOPRINT® platform to deliver customized microfluidic glass chips—optimized for applications in diagnostics, drug discovery, and personalized medicine.
A Glimpse Into the Future of Microfluidics
With trends like personalized healthcare, liquid biopsy, and single-cell analysis (SCA) on the rise, the demand for scalable, high-precision microfluidic platforms is accelerating. Glass microfluidics is uniquely positioned to meet this demand, supporting use cases such as:
Join the Revolution in Microfluidics
If you're active in biotechnology, medical technology, or microfluidics research and development (R&D), the MF 2025 is an unmissable opportunity. Meet with the FEMTOprint SA team to:
